Geller Family Office Services LLC maintained its position in Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,900 shares of the medical research company’s stock at the end of the second quarter. Amgen makes up about 0.2% of Geller Family Office Services LLC’s portfolio, making the stock its 19th largest position. Geller Family Office Services LLC’s holdings in Amgen were worth $289,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Glassman Wealth Services boosted its position in Amgen by 480.0% in the second quarter. Glassman Wealth Services now owns 725 shares of the medical research company’s stock worth $110,000 after buying an additional 600 shares during the period. Oakworth Capital Inc. boosted its position in Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares during the period. Integrated Wealth Management boosted its stake in shares of Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock worth $141,000 after buying an additional 3 shares during the last quarter. Delta Asset Management LLC TN boosted its stake in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares during the last quarter. Finally, Capital Advisors Ltd. LLC boosted its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares during the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 167.34 on Tuesday. The stock’s 50 day moving average price is $171.51 and its 200 day moving average price is $161.44. The company has a market capitalization of $125.23 billion, a PE ratio of 17.12 and a beta of 0.94. Amgen Inc. has a 12-month low of $138.06 and a 12-month high of $176.85.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.10. The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. Amgen’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the firm posted $2.57 EPS. On average, equities research analysts forecast that Amgen Inc. will post $11.36 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were issued a dividend of $1.00 per share. The ex-dividend date of this dividend was Monday, August 15th. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.39%. Amgen’s dividend payout ratio is 40.90%.
A number of equities research analysts have recently issued reports on the stock. Leerink Swann reissued a “hold” rating on shares of Amgen in a research report on Saturday, September 17th. Credit Suisse Group AG set a $206.00 target price on shares of Amgen and gave the company a “buy” rating in a research report on Saturday, September 17th. Vetr raised shares of Amgen from a “hold” rating to a “buy” rating and set a $159.50 target price for the company in a research report on Monday, June 13th. Jefferies Group reissued a “buy” rating and issued a $187.00 target price on shares of Amgen in a research report on Wednesday, July 13th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $157.00 target price on shares of Amgen in a research report on Friday, July 15th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $185.06.
In related news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.